AP
DXCM icon

Antipodes Partners’s DexCom DXCM Stock Holding History

Antipodes Partners’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-554
Closed -$34.8K – 137
2026
Q1 		$34.8K Sell
554
-304
-35% -$21.2K ﹤0.01% 111
2025
Q4 		$57K Sell
858
-759
-47% -$49.1K ﹤0.01% 104
2025
Q3 		$109K Buy
1,617
+773
+92% +$61.2K ﹤0.01% 86
2025
Q2 		$73.7K Sell
844
-1,118
-57% -$87.6K ﹤0.01% 79
2025
Q1 		$134K Buy
+1,962
New +$160K ﹤0.01% 64

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.84B AUM 22.63% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Antipodes Partners's DXCM Position: Q2 2026 in Review

Antipodes Partners sold out of DexCom (DXCM) in Q2 2026, closing a stake of 554 shares — an estimated $34.8K sold.

Antipodes Partners first reported a position in DXCM in Q1 2025 and held it in 5 quarters. The position peaked at $134K in Q1 2025. 537 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Antipodes Partners reported no remaining DexCom position as of Q2 2026 after selling out during the quarter.
  • Antipodes Partners sold 554 DexCom shares in Q2 2026, an estimated $34.8K.
  • Antipodes Partners first reported a position in DexCom in Q1 2025 and held it in 5 quarters.
  • Antipodes Partners's DexCom position peaked at $134K in Q1 2025.
  • 537 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.